Clinical trials: Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL)
Refractory T-Cell Lymphoma, Relapsed T-Cell Lymphoma
Daratumumab Plus Gemcitabine, Dexamethasone, Cisplatin in pt R/R CD38+ PTCL-NOS, AITL and TFH
FIL_Dara-GDP is a phase II, open label, multicenter clinical trial. The sponsor of this clinical trial is Fondazione Italiana Linfomi (FIL).
- Trial name
- NCT04251065
- Testing
- Daratumumab
- Where
- 7 sites in Italy
- Volunteers
- 8 people
- Sponsor
- Fondazione Italiana Linfomi - ETS
Angioimmunoblastic T-cell Lymphoma
Sintilimab in Combination With Chidamide in Refractory and Relapsed AITL
Angioimmunoblastic T-cell lymphoma (AITL) belongs to a subtype of peripheral T-cell lymphoma (PTCL) and is also a distinct type of non-Hodgkin lymphoma (NHL).
- Trial name
- NCT04831710
- Testing
- Sintilimab, Chidamide
- Where
- China
- Volunteers
- 83 people
- Sponsor
- Sun Yat-sen University
Angioimmunoblastic T-cell Lymphoma
Clinical Study of Mitoxantrone Liposome and Azacitidine in the Treatment of R/R AITL
This study is an open-label, single-arm Phase Ib/II clinical trial designed to evaluate the safety and efficacy of the combination therapy with mitoxantrone liposome and azacitidine in the treatment of relapsed/refractory…
- Trial name
- NCT06224842
- Testing
- mitoxantrone liposome 16 and azacitidine, mitoxantrone liposome 18 and azacitidine, mitoxantrone liposome 20 and azacitidine
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Huijing Wu
Relapsed or Refractory T-cell Lymphomas
A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)
The purpose of this study is to test the safety, tolerability, efficacy, and drug levels of BMS-986369 (Golcadomide) in participants with relapsed or refractory T-cell lymphomas in Japan (GOLSEEK-3).
- Trial name
- NCT06035497
- Testing
- BMS-986369
- Where
- 40 sites in Japan
- Volunteers
- 83 people
- Sponsor
- Bristol-Myers Squibb
Angioimmunoblastic T-cell Lymphoma, Chemotherapy Effect
Rituximab Combined With Chidamide and Lenalidomide for r/r AITL
This study is designed to explore the effeicency and toxicities of rituximab combined with chidamide and lenalidomide in patients with relapsed or refractory AITL.
- Conditions
- Angioimmunoblastic T-cell Lymphoma, Chemotherapy Effect, Chemotherapeutic Toxicity
- Trial name
- AITL (NCT04319601)
- Testing
- Rituximab
- Where
- China
- Volunteers
- 26 people
- Sponsor
- Zhejiang Cancer Hospital
Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL), Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL)
A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.
This clinical trial is studying the safety and potential anti-tumor activity of an investigational drug called ARV-393 in patients diagnosed with advanced Relapsed/Refractory non-Hodgkin's lymphoma (R/R NHL) to determine if…
- Trial name
- NCT06393738
- Testing
- ARV-393, Glofitamab
- Where
- 21 sites in United States, Australia and 3 more
- Volunteers
- 329 people
- Sponsor
- Arvinas Inc.